Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12 Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Key Points Patients with relapsed or refractory transformed indolent lymphoma and DLBCL have similar outcomes with salvage therapy and ASCT. This therapy should be considered the standard of care for previously treated transformed indolent lymphoma.

authors

Kouroukis, Tom
Kuruvilla, John
MacDonald, David A
Kouroukis, C Tom
Cheung, Matthew
Olney, Harold J
Turner, A Robert
Anglin, Peter
Seftel, Matthew
Ismail, Walid Sabry
Luminari, Stefano
Couban, Stephen
Baetz, Tara
Meyer, Ralph
Hay, Annette E
Shepherd, Lois
Djurfeldt, Marina S
Alamoudi, Sameer
Chen, Bingshu E
Crump, Michael

status

published

publication date

August 6, 2015

has subject area

1102 Cardiorespiratory Medicine and Haematology (FoR)
1103 Clinical Sciences (FoR)
1114 Paediatrics and Reproductive Medicine (FoR)
Adult (MeSH)
Aged (MeSH)
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Cisplatin (MeSH)
Cytarabine (MeSH)
Deoxycytidine (MeSH)
Dexamethasone (MeSH)
Etoposide (MeSH)
Female (MeSH)
Follow-Up Studies (MeSH)
Gemcitabine (MeSH)
Hematopoietic Stem Cell Transplantation (MeSH)
Humans (MeSH)
Immunology (Science Metrix)
Lymphoma, Large B-Cell, Diffuse (MeSH)
Lymphoma, Non-Hodgkin (MeSH)
Male (MeSH)
Middle Aged (MeSH)
Multivariate Analysis (MeSH)
Prognosis (MeSH)
Recurrence (MeSH)
Salvage Therapy (MeSH)
Survival Analysis (MeSH)
Time Factors (MeSH)
Transplantation, Autologous (MeSH)

published in

Blood Journal